- In February 2024, Pfizer Inc., the original developer of Lyrica (brand name for Pregabalin), announced expanded availability of its generic Pregabalin in several emerging markets including Latin America and Southeast Asia. This move is aimed at improving access to essential neuropathic pain and epilepsy treatments in lower-income countries, thereby reinforcing Pfizer’s leadership in the global CNS therapeutics segment
- In January 2024, Teva Pharmaceutical Industries Ltd. launched a new extended-release formulation of Pregabalin in the U.S. market. Designed for once-daily dosing, this formulation aims to improve patient adherence in managing chronic neuropathic pain and fibromyalgia, particularly among elderly patients
- In October 2023, Dr. Reddy’s Laboratories received FDA approval for its Pregabalin extended-release tablets, 165 mg and 330 mg, marking a significant step in the company’s strategy to diversify its complex generics portfolio in the U.S. market
- In August 2023, Sun Pharmaceutical Industries Ltd. initiated clinical trials in India for a combination therapy of Pregabalin and Duloxetine, targeting treatment-resistant neuropathic pain. The trial aims to evaluate the synergistic effect of dual therapy on diabetic neuropathy and fibromyalgia
- In May 2023, Zydus Lifesciences introduced a novel fixed-dose combination (FDC) of Pregabalin and Nortriptyline in India. This FDC is designed to offer comprehensive pain relief in patients suffering from peripheral neuropathic conditions, enhancing Zydus' neurology product portfolio
- In March 2023, Lupin Limited launched Pregabalin oral solution in the European market following the EMA's approval. The new formulation is intended for patients with swallowing difficulties, particularly in the geriatric and pediatric population
